Group 1 - The biotechnology company Baiji Pharmaceutical-B (02659) has completed its subscription period from December 2 to December 5, with trading expected to commence on December 10 [1] - Market statistics indicate that Baiji Pharmaceutical has secured HKD 269.21 billion in margin loans from brokers, resulting in an oversubscription of 2,690.8 times against the public offering amount of HKD 100 million [1] - The company plans to issue 37.912 million H-shares, with 10% allocated for public offering at a price of HKD 26.38 per share, aiming to raise HKD 1 billion [1] Group 2 - The entry fee for one board lot of 100 shares is HKD 2,664.6 [1] - CICC and Haitong International are the joint sponsors for the offering [1] - Baiji Pharmaceutical has introduced cornerstone investors including Anke Biotechnology (300009), DC Alpha SPC, and Guotai Junan Securities, with an investment amount of HKD 200 million [1]
宝济药业-B招股结束 孖展认购额录得2692.1亿港元 超购2690.8倍